Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1996 Jun 25;93(13):6814–6818. doi: 10.1073/pnas.93.13.6814

Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.

J M Connett 1, C J Anderson 1, L W Guo 1, S W Schwarz 1, K R Zinn 1, B E Rogers 1, B A Siegel 1, G W Philpott 1, M J Welch 1
PMCID: PMC39110  PMID: 8692901

Abstract

67Cu (t1/2 = 62 h) has demonstrated potential as a radionuclide for radioimmunotherapy, but limited availability severely restricts its widespread use. 64Cu (t1/2 = 12.8 h) has been shown to have comparable effectiveness in vitro and in vivo. The present study was undertaken to examine the therapeutic potential of 64Cu- and 67Cu-bromoacetamidobenzyl-1,4,8,11-tetraazacyclotetradeca ne-N, N',N",N"'-tetraacetic acid (BAT)-2-iminothiolane (2IT)-1A3 (1A3 is a mouse anti-human colorectal cancer mAb) for treatment of GW39 human colon carcinoma carried in hamster thighs. Hamsters were injected with 64Cu- or 67Cu-BAT-2IT-1A3 or Cu-labeled nonspecific IgG (MOPC) or saline. Hamsters were killed 6-7 months after therapy or when tumors were > or = 10 g. Of the hamsters with small tumors (mean weight 0.43 +/- 0.25 g), 87.5% were disease-free 7 months after treatment with 2 mCi (1 Ci = 37 GBq) of 64Cu-BAT-2IT-1A3 or 0.4 MCi of 67Cu-BAT-2IT-1A3. The mean tumor doses at these activities of 64Cu- and 67Cu-BAT-2IT-1A3 were 586 and 1269 rad (1 rad = 0.01 Gy), respectively. In contrast, 76% of hamsters treated with 2 mCi of 64Cu-BAT-2IT-MOPC or 0.4 mCi of 67Cu-BAT-2IT-MOPC had to be killed before 6 months because of tumor regrowth. When hamsters with larger tumors (mean weight 0.66 +/- 0.11 g) were treated with 64Cu- or 67Cu-BAT-2IT-1A3, survival was extended compared with controls, but only one animal remained tumor-free to 6 months. These results demonstrate that 64Cu- and 67Cu-BAT-2IT-1A3 given in a single administered dose can eradicate small tumors without significant host toxicity, but additional strategies to deliver higher tumor doses will be needed for larger tumors.

Full text

PDF
6814

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson C. J., Connett J. M., Schwarz S. W., Rocque P. A., Guo L. W., Philpott G. W., Zinn K. R., Meares C. F., Welch M. J. Copper-64-labeled antibodies for PET imaging. J Nucl Med. 1992 Sep;33(9):1685–1691. [PubMed] [Google Scholar]
  2. Apelgot S., Coppey J., Gaudemer A., Grisvard J., Guille E., Sasaki I., Sissoeff I. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol. 1989 Mar;55(3):365–384. doi: 10.1080/09553008914550421. [DOI] [PubMed] [Google Scholar]
  3. Badger C. C., Krohn K. A., Shulman H., Flournoy N., Bernstein I. D. Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies. Cancer Res. 1986 Dec;46(12 Pt 1):6223–6228. [PubMed] [Google Scholar]
  4. Beaumier P. L., Venkatesan P., Vanderheyden J. L., Burgua W. D., Kunz L. L., Fritzberg A. R., Abrams P. G., Morgan A. C., Jr 186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice. Cancer Res. 1991 Jan 15;51(2):676–681. [PubMed] [Google Scholar]
  5. Blumenthal R. D., Sharkey R. M., Haywood L., Natale A. M., Wong G. Y., Siegel J. A., Kennel S. J., Goldenberg D. M. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992 Nov 1;52(21):6036–6044. [PubMed] [Google Scholar]
  6. Blumenthal R. D., Sharkey R. M., Kashi R., Goldenberg D. M. Comparison of therapeutic efficacy and host toxicity of two different 131I-labelled antibodies and their fragments in the GW-39 colonic cancer xenograft model. Int J Cancer. 1989 Aug 15;44(2):292–300. doi: 10.1002/ijc.2910440218. [DOI] [PubMed] [Google Scholar]
  7. Buchegger F., Pèlegrin A., Delaloye B., Bischof-Delaloye A., Mach J. P. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J Nucl Med. 1990 Jun;31(6):1035–1044. [PubMed] [Google Scholar]
  8. Buchegger F., Vacca A., Carrel S., Schreyer M., Mach J. P. Radioimmunotherapy of human colon carcinoma by 131I-labelled monoclonal anti-CEA antibodies in a nude mouse model. Int J Cancer. 1988 Jan 15;41(1):127–134. doi: 10.1002/ijc.2910410123. [DOI] [PubMed] [Google Scholar]
  9. Buchsbaum D. J., Langmuir V. K., Wessels B. W. Experimental radioimmunotherapy. Med Phys. 1993 Mar-Apr;20(2 Pt 2):551–567. doi: 10.1118/1.597142. [DOI] [PubMed] [Google Scholar]
  10. Buchsbaum D. J., Lawrence T. S., Roberson P. L., Heidorn D. B., Ten Haken R. K., Steplewski Z. Comparison of 131I- and 90Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts. Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):629–638. doi: 10.1016/0360-3016(93)90009-k. [DOI] [PubMed] [Google Scholar]
  11. Buchsbaum D. J., Wahl R. L., Normolle D. P., Kaminski M. S. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res. 1992 Dec 1;52(23):6476–6481. [PubMed] [Google Scholar]
  12. Buras R. R., Beatty B. G., Williams L. E., Wanek P. M., Harris J. B., Hill L. R., Beatty J. D. Radioimmunotherapy of human colon cancer in nude mice. Arch Surg. 1990 May;125(5):660–664. doi: 10.1001/archsurg.1990.01410170108023. [DOI] [PubMed] [Google Scholar]
  13. Ceriani R. L., Blank E. W. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule. Cancer Res. 1988 Aug 15;48(16):4664–4672. [PubMed] [Google Scholar]
  14. Cutler P. D., Schwarz S. W., Anderson C. J., Connett J. M., Welch M. J., Philpott G. W., Siegel B. A. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J Nucl Med. 1995 Dec;36(12):2363–2371. [PubMed] [Google Scholar]
  15. Deshpande S. V., DeNardo S. J., Meares C. F., McCall M. J., Adams G. P., Moi M. K., DeNardo G. L. Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med. 1988 Feb;29(2):217–225. [PubMed] [Google Scholar]
  16. Esteban J. M., Hyams D. M., Beatty B. G., Merchant B., Beatty J. D. Radioimmunotherapy of human colon carcinomatosis xenograft with 90Y-ZCE025 monoclonal antibody: toxicity and tumor phenotype studies. Cancer Res. 1990 Feb 1;50(3 Suppl):989s–992s. [PubMed] [Google Scholar]
  17. Fenwick J. R., Philpott G. W., Connett J. M. Biodistribution and histological localization of anti-human colon cancer monoclonal antibody (MAb) 1A3: the influence of administered MAb dose on tumor uptake. Int J Cancer. 1989 Dec 15;44(6):1017–1027. doi: 10.1002/ijc.2910440614. [DOI] [PubMed] [Google Scholar]
  18. Goldenberg D. M., Witte S., Elster K. GW-39: a new human tumor serially transplantable in the golden hamster. Transplantation. 1966 Nov;4(6):760–763. doi: 10.1097/00007890-196611000-00013. [DOI] [PubMed] [Google Scholar]
  19. Huneke R. B., Pippin C. G., Squire R. A., Brechbiel M. W., Gansow O. A., Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 1992 Oct 15;52(20):5818–5820. [PubMed] [Google Scholar]
  20. Lindmo T., Boven E., Cuttitta F., Fedorko J., Bunn P. A., Jr Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984 Aug 3;72(1):77–89. doi: 10.1016/0022-1759(84)90435-6. [DOI] [PubMed] [Google Scholar]
  21. Macklis R. M., Kinsey B. M., Kassis A. I., Ferrara J. L., Atcher R. W., Hines J. J., Coleman C. N., Adelstein S. J., Burakoff S. J. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988 May 20;240(4855):1024–1026. doi: 10.1126/science.2897133. [DOI] [PubMed] [Google Scholar]
  22. McCall M. J., Diril H., Meares C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug Chem. 1990 May-Jun;1(3):222–226. doi: 10.1021/bc00003a007. [DOI] [PubMed] [Google Scholar]
  23. Molthoff C. F., Pinedo H. M., Schlüper H. M., Boven E. Influence of dose and schedule on the therapeutic efficacy of 131I-labelled monoclonal antibody 139H2 in a human ovarian cancer xenograft model. Int J Cancer. 1992 Feb 1;50(3):474–480. doi: 10.1002/ijc.2910500324. [DOI] [PubMed] [Google Scholar]
  24. Philpott G. W., Schwarz S. W., Anderson C. J., Dehdashti F., Connett J. M., Zinn K. R., Meares C. F., Cutler P. D., Welch M. J., Siegel B. A. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J Nucl Med. 1995 Oct;36(10):1818–1824. [PubMed] [Google Scholar]
  25. Philpott G. W., Siegel B. A., Schwarz S. W., Connett J. M., Rocque P. A., Fleshman J. W., Wallis J. W., Baumann M., Sun Y., Martell A. E. Immunoscintigraphy with a new indium-111-labeled monoclonal antibody (MAb 1A3) in patients with colorectal cancer. Dis Colon Rectum. 1994 Aug;37(8):782–792. doi: 10.1007/BF02050143. [DOI] [PubMed] [Google Scholar]
  26. Sharkey R. M., Kaltovich F. A., Shih L. B., Fand I., Govelitz G., Goldenberg D. M. Radioimmunotherapy of human colonic cancer xenografts with 90Y labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 1988 Jun 1;48(11):3270–3275. [PubMed] [Google Scholar]
  27. Sharkey R. M., Motta-Hennessy C., Pawlyk D., Siegel J. A., Goldenberg D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990 Apr 15;50(8):2330–2336. [PubMed] [Google Scholar]
  28. Sharkey R. M., Pykett M. J., Siegel J. A., Alger E. A., Primus F. J., Goldenberg D. M. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1987 Nov 1;47(21):5672–5677. [PubMed] [Google Scholar]
  29. Siler K., Eggensperger D., Hand P. H., Milenic D. E., Miller L. S., Houchens D. P., Hinkle G., Schlom J. Therapeutic efficacy of a high-affinity anticarcinoembryonic antigen monoclonal antibody (COL-1). Biotechnol Ther. 1993;4(3-4):163–181. [PubMed] [Google Scholar]
  30. Wahl R. L., Parker C. W., Philpott G. W. Improved radioimaging and tumor localization with monoclonal F(ab')2. J Nucl Med. 1983 Apr;24(4):316–325. [PubMed] [Google Scholar]
  31. Wessels B. W., Rogus R. D. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 1984 Sep-Oct;11(5):638–645. doi: 10.1118/1.595559. [DOI] [PubMed] [Google Scholar]
  32. Zalcberg J. R., Thompson C. H., Lichtenstein M., McKenzie I. F. Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies. J Natl Cancer Inst. 1984 Mar;72(3):697–704. [PubMed] [Google Scholar]
  33. Zalutsky M. R., McLendon R. E., Garg P. K., Archer G. E., Schuster J. M., Bigner D. D. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. Cancer Res. 1994 Sep 1;54(17):4719–4725. [PubMed] [Google Scholar]
  34. Zinn K. R., Chaudhuri T. R., Cheng T. P., Morris J. S., Meyer W. A., Jr Production of no-carrier-added 64Cu from zinc metal irradiated under boron shielding. Cancer. 1994 Feb 1;73(3 Suppl):774–778. doi: 10.1002/1097-0142(19940201)73:3+<774::aid-cncr2820731305>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES